Pacira BioSciences Inc (NASDAQ: PCRX) has reported earnings for its second fiscal quarter (ending June 30) of $0.41 versus $0.56 for the same period a year ago. For the latest four quarters through June 30, E.P.S. were $1.37 compared to $-0.10 a year ago.
Recent Price Action
Pacira BioSciences Inc (NASDAQ: PCRX) stock closed at $19.54 on 7/30/24 after a decline of -4.0%. NORMAL trading volume accompanied the decline. The stock has declined -3.3% during the last week and has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, PCRX is expected to continue to be an important Value Builder.
Pacira BioSciences has a current Value Trend Rating of C (Low Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Pacira BioSciences has a good Appreciation Score of 82 but a very low Power Rating of 9, producing the Low Neutral Value Trend Rating.
Rating Review
In light of this new information and negative market action we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment